Profile
Mark Reddish is currently working as Vice President-Operation at Metrodora Therapeutics, Inc. He previously worked as Senior Director-Research Immunology at Biomira, Inc. from 1991 to 1998, Vice President-Product Development at ID Biomedical Corp.
from 1998 to 2005, and as an Independent Director at Marker Therapeutics, Inc. from 2014 to 2018.
He completed his undergraduate degree from the University of Massachusetts.
Mark Reddish active positions
| Companies | Position | Start |
|---|---|---|
Metrodora Therapeutics, Inc. | Chief Operating Officer | - |
Former positions of Mark Reddish
| Companies | Position | End |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Director/Board Member | 17/10/2018 |
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Corporate Officer/Principal | 01/01/2005 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Develops and researches products to monitor and treat cancer | Corporate Officer/Principal | 01/01/1998 |
Training of Mark Reddish
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Health Technology |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Develops and researches products to monitor and treat cancer | Health Services |
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Metrodora Therapeutics, Inc. |
- Stock Market
- Insiders
- Mark Reddish
















